Xencor (XNCR) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98401F1057

Anti-Cancer, Autoimmune, Monoclonal Antibody, Cytokine Therapeutics

Xencor, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative treatments for cancer and autoimmune diseases. The company's primary focus is on creating engineered monoclonal antibody and cytokine therapeutics that can effectively target and combat life-threatening diseases.

Xencor's product pipeline is robust, with several promising therapies in various stages of development. One of its notable products is Sotrovimab, which targets the SARS-CoV-2 virus, providing a potential solution for COVID-19 patients. Additionally, the company offers Ultomiris for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as Monjuvi for relapsed or refractory diffuse large B-cell lymphoma.

The company is also actively developing several bispecific antibodies, including Plamotamab, which is in Phase I clinical trials for non-Hodgkin lymphoma, and Vudalimab, which is in Phase II clinical trials for metastatic castration-resistant prostate cancer and other solid tumor types. Furthermore, Xencor is exploring XmAb306 for solid tumors, XmAb104 for selected solid tumors, XmAb564 for autoimmune diseases, and AMG 509 for prostate cancer, among others.

Xencor's commitment to innovation is evident in its diverse pipeline, which also includes XmAb819 for renal cell carcinoma, XmAb541 for ovarian cancer, XmAb662 for solid tumors, VIR-3434 for hepatitis B virus infection, and VIR-2482 for hepatitis B virus. The company is also developing AIMab7195 to reduce blood serum levels of IgE, Obexelimab for autoimmune diseases, and Xpro1595 for Alzheimer's disease and depression.

With a strong foundation established in 1997, Xencor, Inc. is headquartered in Pasadena, California, and continues to drive progress in the biopharmaceutical industry. For more information, visit their website at https://www.xencor.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Xencor (XNCR) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Xencor (XNCR) - Stock Price & Dividends

XNCR Stock Overview

Market Cap in USD 1,420m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2013-12-03

XNCR Stock Ratings

Growth 5y -3.01
Fundamental -31.1
Dividend -
Rel. Performance vs Sector -2.08
Analysts 4.38/5
Fair Price Momentum 24.31 USD
Fair Price DCF 21.93 USD

XNCR Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

XNCR Growth Ratios

Growth 12m -13.62%
Growth Correlation 12m -22%
Growth Correlation 3m -12%
CAGR 5y -5.36%
CAGR/Mean DD 5y -0.15
Sharpe Ratio 12m -0.40
Alpha vs SP500 12m -40.61
Beta vs SP500 5y weekly 0.96
ValueRay RSI 79.92
Volatility GJR Garch 1y 51.67%
Price / SMA 50 7.69%
Price / SMA 200 12.5%
Current Volume 449.7k
Average Volume 20d 707.3k

External Links for XNCR Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of XNCR stocks?
As of May 30, 2024, the stock is trading at USD 23.40 with a total of 449,719 shares traded.
Over the past week, the price has changed by -1.56%, over one month by +11.06%, over three months by +2.68% and over the past year by -13.62%.
What are the forecast for XNCR stock price target?
According to ValueRays Forecast Model, XNCR Xencor will be worth about 27.1 in May 2025. The stock is currently trading at 23.40. This means that the stock has a potential upside of +15.68%.
Issuer Forecast Upside
Wallstreet Target Price 37.3 59.3
Analysts Target Price 43.6 86.2
ValueRay Target Price 27.1 15.7